List of Tables
Table 1: Number of Products under Development for Optic Neuropathy
Table 2: Number of Products under Development by Companies, Optic Neuropathy
Table 3: Number of Products under Development by Universities/Institutes, Optic Neuropathy
Table 4: Products under Development by Companies, Optic Neuropathy
Table 5: Products under Development by Universities/Institutes, Optic Neuropathy
Table 6: Number of Products under Development for Glaucoma
Table 7: Number of Products under Development by Companies, Glaucoma
Table 8: Number of Products under Development by Universities/Institutes, Glaucoma
Table 9: Products under Development by Companies, Glaucoma
Table 10: Products under Development by Universities/Institutes, Glaucoma
Table 11: Number of Products under Development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Table 12: Number of Products under Development by Companies, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Table 13: Number of Products under Development by Universities/Institutes, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Table 14: Products under Development by Companies, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Table 15: Products under Development by Universities/Institutes, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Table 16: Number of Products under Development for Optic Neuritis
Table 17: Number of Products under Development by Companies, Optic Neuritis
Table 18: Number of Products under Development by Universities/Institutes, Optic Neuritis
Table 19: Products under Development by Companies, Optic Neuritis
Table 20: Products under Development by Universities/Institutes, Optic Neuritis
Table 21: Number of Products by Stage and Target, Optic Neuropathy
Table 22: Number of Products by Stage and Mechanism of Action, Optic Neuropathy
Table 23: Number of Products by Stage and Route of Administration, Optic Neuropathy
Table 24: Number of Products by Stage and Molecule Type, Optic Neuropathy
Table 25: Number of Products by Stage and Target, Glaucoma
Table 26: Number of Products by Stage and Mechanism of Action, Glaucoma
Table 27: Number of Products by Stage and Route of Administration, Glaucoma
Table 28: Number of Products by Stage and Molecule Type, Glaucoma
Table 29: Number of Products by Stage and Target, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Table 30: Number of Products by Stage and Mechanism of Action, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Table 31: Number of Products by Stage and Route of Administration, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Table 32: Number of Products by Stage and Molecule Type, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Table 33: Number of Products by Stage and Target, Optic Neuritis
Table 34: Number of Products by Stage and Mechanism of Action, Optic Neuritis
Table 35: Number of Products by Stage and Route of Administration, Optic Neuritis
Table 36: Number of Products by Stage and Molecule Type, Optic Neuritis
Table 37: Optic Neuropathy – Pipeline by Amgen Inc, H2 2018
Table 38: Optic Neuropathy – Pipeline by Ironwood Pharmaceuticals Inc, H2 2018
Table 39: Optic Neuropathy – Pipeline by Quark Pharmaceuticals Inc, H2 2018
Table 40: Optic Neuropathy – Pipeline by Regenera Pharma Ltd, H2 2018
Table 41: Optic Neuropathy – Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Table 42: Glaucoma – Pipeline by AC Immune SA, H2 2018
Table 43: Glaucoma – Pipeline by Aerie Pharmaceuticals Inc, H2 2018
Table 44: Glaucoma – Pipeline by Allergan Plc, H2 2018
Table 45: Glaucoma – Pipeline by Altacor Ltd, H2 2018
Table 46: Glaucoma – Pipeline by Amarantus Bioscience Holdings Inc, H2 2018
Table 47: Glaucoma – Pipeline by Amgen Inc, H2 2018
Table 48: Glaucoma – Pipeline by Annexon Inc, H2 2018
Table 49: Glaucoma – Pipeline by Astellas Pharma Inc, H2 2018
Table 50: Glaucoma – Pipeline by Bial - Portela & Ca SA, H2 2018
Table 51: Glaucoma – Pipeline by BioAxone BioSciences Inc, H2 2018
Table 52: Glaucoma – Pipeline by Can-Fite BioPharma Ltd, H2 2018
Table 53: Glaucoma – Pipeline by Cellix Bio Pvt Ltd, H2 2018
Table 54: Glaucoma – Pipeline by Certa Therapeutics Pty Ltd, H2 2018
Table 55: Glaucoma – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2018
Table 56: Glaucoma – Pipeline by D. Western Therapeutics Institute Inc, H2 2018
Table 57: Glaucoma – Pipeline by Disarm Therapeutics Inc, H2 2018
Table 58: Glaucoma – Pipeline by Dompe Farmaceutici SpA, H2 2018
Table 59: Glaucoma – Pipeline by Elsalys Biotech SA, H2 2018
Table 60: Glaucoma – Pipeline by EyePoint Pharmaceuticals Inc, H2 2018
Table 61: Glaucoma – Pipeline by Eyevensys SAS, H2 2018
Table 62: Glaucoma – Pipeline by Fortress Biotech Inc, H2 2018
Table 63: Glaucoma – Pipeline by Gene Signal International SA, H2 2018
Table 64: Glaucoma – Pipeline by Glaukos Corp, H2 2018
Table 65: Glaucoma – Pipeline by Graybug Vision Inc, H2 2018
Table 66: Glaucoma – Pipeline by Han Wha Pharma Co Ltd, H2 2018
Table 67: Glaucoma – Pipeline by Handok Inc, H2 2018
Table 68: Glaucoma – Pipeline by HitGen LTD, H2 2018
Table 69: Glaucoma – Pipeline by ID Pharma Co Ltd, H2 2018
Table 70: Glaucoma – Pipeline by InMed Pharmaceuticals Inc, H2 2018
Table 71: Glaucoma – Pipeline by Inspyr Therapeutics Inc, H2 2018
Table 72: Glaucoma – Pipeline by Isarna Therapeutics GmbH, H2 2018
Table 73: Glaucoma – Pipeline by Kowa Co Ltd, H2 2018
Table 74: Glaucoma – Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2018
Table 75: Glaucoma – Pipeline by Laboratorios SALVAT SA, H2 2018
Table 76: Glaucoma – Pipeline by Laboratorios Sophia SA de CV, H2 2018
Table 77: Glaucoma – Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2018
Table 78: Glaucoma – Pipeline by MimeTech Srl, H2 2018
Table 79: Glaucoma – Pipeline by Nemus Bioscience Inc, H2 2018
Table 80: Glaucoma – Pipeline by Neurim Pharmaceuticals Ltd, H2 2018
Table 81: Glaucoma – Pipeline by NicOx SA, H2 2018
Table 82: Glaucoma – Pipeline by NoNO Inc, H2 2018
Table 83: Glaucoma – Pipeline by Novaliq GmbH, H2 2018
Table 84: Glaucoma – Pipeline by Novartis AG, H2 2018
Table 85: Glaucoma – Pipeline by Ocular Therapeutix Inc, H2 2018
Table 86: Glaucoma – Pipeline by Oculis ehf, H2 2018
Table 87: Glaucoma – Pipeline by Ohr Pharmaceutical Inc, H2 2018
Table 88: Glaucoma – Pipeline by Oncolys BioPharma Inc, H2 2018
Table 89: Glaucoma – Pipeline by Pivot Pharmaceuticals Inc, H2 2018
Table 90: Glaucoma – Pipeline by Profarma, H2 2018
Table 91: Glaucoma – Pipeline by Q BioMed Inc, H2 2018
Table 92: Glaucoma – Pipeline by Quark Pharmaceuticals Inc, H2 2018
Table 93: Glaucoma – Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Table 94: Glaucoma – Pipeline by ReNetX Bio, H2 2018
Table 95: Glaucoma – Pipeline by Santen Pharmaceutical Co Ltd, H2 2018
Table 96: Glaucoma – Pipeline by Senju Pharmaceutical Co Ltd, H2 2018
Table 97: Glaucoma – Pipeline by Shire Plc, H2 2018
Table 98: Glaucoma – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2018
Table 99: Glaucoma – Pipeline by Sylentis SAU, H2 2018
Table 100: Glaucoma – Pipeline by Taejoon Pharm Co Ltd, H2 2018
Table 101: Glaucoma – Pipeline by TikoMed AB, H2 2018
Table 102: Glaucoma – Pipeline by Unity Biotechnology Inc, H2 2018
Table 103: Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Pipeline by Alkeus Pharmaceuticals Inc, H2 2018
Table 104: Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Pipeline by Bactevo Ltd, H2 2018
Table 105: Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Pipeline by Biovista Inc, H2 2018
Table 106: Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Pipeline by Fortify Therapeutics Inc, H2 2018
Table 107: Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Pipeline by GenSight Biologics SA, H2 2018
Table 108: Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Pipeline by Ixchel Pharma LLC, H2 2018
Table 109: Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Pipeline by Khondrion BV, H2 2018
Table 110: Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Pipeline by Mitobridge Inc, H2 2018
Table 111: Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Pipeline by Mitotech SA, H2 2018
Table 112: Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Pipeline by Santhera Pharmaceuticals Holding AG, H2 2018
Table 113: Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Pipeline by Spark Therapeutics Inc, H2 2018
Table 114: Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Pipeline by Stealth BioTherapeutics Inc, H2 2018
Table 115: Optic Neuritis – Pipeline by Bionure Farma SL, H2 2018
Table 116: Optic Neuritis – Pipeline by Commence Bio Inc, H2 2018
Table 117: Optic Neuritis – Pipeline by Lipocure Ltd, H2 2018
Table 118: Optic Neuritis – Pipeline by Meta-IQ ApS, H2 2018
Table 119: Optic Neuritis – Pipeline by Mitochon Pharmaceuticals Inc, H2 2018
Table 120: Optic Neuritis – Pipeline by Teijin Pharma Ltd, H2 2018
Table 121: Optic Neuropathy – Dormant Projects, H2 2018
Table 122: Glaucoma – Dormant Projects, H2 2018
Table 123: Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Dormant Projects, H2 2018
Table 124: Optic Neuritis – Dormant Projects, H2 2018
Table 125: Optic Neuropathy – Discontinued Products, H2 2018
Table 126: Glaucoma – Discontinued Products, H2 2018
Table 127: Optic Neuritis – Discontinued Products, H2 2018